By Fineline Cube 
US-based sequencing solutions provider PacBio (NASDAQ: PACB) has appointed China’s Haorui Gene as an official distributor in China. This collaboration aims to enhance accessibility to PacBio’s HiFi long-read sequencing technology in both clinical and research applications, particularly in transfusion medicine and hematology. These fields require highly precise and comprehensive genomic data to optimize patient outcomes.
Distribution Agreement
Under the agreement, Haorui Gene will distribute PacBio’s Vega platform across China. Integrated with Haorui Gene’s existing product portfolio, the platform will provide end-to-end solutions for clinical laboratories, blood centers, and genomics institutions seeking to develop more accurate and complete blood group profiles.
Haorui Gene’s Expertise
Established in 2020, Haorui Gene has rapidly emerged as a leader in blood typing genomics. The company currently operates seven Sequel II and three Revio systems nationwide, supporting large-scale initiatives in HLA typing, blood group genotyping, and rare blood type identification. This partnership with PacBio further solidifies Haorui Gene’s position as a key player in the genomics field.-Fineline Info & Tech